Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OABI by emailGet an email when OABI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OABI, unsubscribe in one click. Privacy
📣 What OABI Says Is Next
second half of · “They expect to provide further updates on the potentially registrational IMVT-1402 difficult-to-treat rheumatoid arthritis program and report topline data from the proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus in the second half of calendar year 2026.”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “Topline results of the Phase 2a trial evaluating TEV-'408 for celiac disease continue to be expected in the second half of 2026 .”
Company press release, Aug 6, 2026 · SEC filing
second half of this year · “Topline results of the Phase 2a trial evaluating TEV-'408 for celiac disease are expected in the second half of this year.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OABI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OABI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.